Telomir Pharmaceuticals (TELO) announced Telomir-1 has captured and stabilized both Silver and the highly reactive Silver in a biologically compatible form. The company said, “This milestone overcomes a major limitation in silver-based medical applications, opening the door for advanced antimicrobial treatments, wound care solutions, and infection-resistant medical coatings.” Telomir is advancing research and development to explore clinical applications of stabilized Silver complexed-Telomir-1 and is evaluating regulatory pathways to bring these innovations to market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TELO:
- Telomir Pharmaceuticals initiated with a Buy at Rodman & Renshaw
- Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
- Telomir Pharmaceuticals files $150M mixed securities shelf
- Biotech Alert: Searches spiking for these stocks today
- Renovaro BioSciences appoints Fuentes as Chief Financial Officer